ArticleImmunity2012
Galectin-1 for neuroprotection?
Article in Immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Article
- Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration.CNS neuroscience & therapeutics · 2024Article
- Galectins-Potential Therapeutic Targets for Neurodegenerative Disorders.International journal of molecular sciences · 2022Review
- Can the administration of platelet lysates to the brain help treat neurological disorders?Cellular and molecular life sciences : CMLS · 2022Review
- Schizophrenia risk ZNF804A interacts with its associated proteins to modulate dendritic morphology and synaptic development.Molecular brain · 2021Article
- Functionalized gold nanoparticles: promising and efficient diagnostic and therapeutic tools for HIV/AIDS.RSC medicinal chemistry · 2020Review
- Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings.The Psychiatric quarterly · 2020Article
- Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences.Current neuropharmacology · 2020Review
- Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders.ACS nano · 2019Article
- Galectin-1 Reduces Neuroinflammation via Modulation of Nitric Oxide-Arginase Signaling in HIV-1 Transfected Microglia: a Gold Nanoparticle-Galectin-1 "Nanoplex" a Possible Neurotherapeutic?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Article
- Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.Stem cells translational medicine · 2017Article
- Modulation of the Mesenchymal Stem Cell Secretome Using Computer-Controlled Bioreactors: Impact on Neuronal Cell Proliferation, Survival and Differentiation.Scientific reports · 2016Article
- Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: Neuroprotective role in maintaining blood brain barrier integrity.Brain research · 2015Article
- Galectin-1 is an interactive protein of selenoprotein M in the brain.International journal of molecular sciences · 2013Article
- Neuroprotection in multiple sclerosis: a therapeutic approach.CNS drugs · 2013Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classically activated microglia (M1) are believed to play a key role in neuronal degeneration in multiple sclerosis (MS). In this issue of Immunity, Starossom et al. (2012) show that Galectin-1 exerts a neuroprotective function through glycosylation-dependent inactivation with M1 cells.
Identifiers
22921113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.